Search

PR-104

PR-15

PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.

Exametazime

It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes. … It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex.

N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. … It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.

Nebicapone

Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose … of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).

Bumadizone

Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis

Benzylfentanyl

Benzylfentanyl (R-4129) is a fentanyl analog opioid that was on the list of Schedule I drugs in America in 1985 due to its structural similarity to fentanyl. … In 2010 it was removed from the list after it was found to have minimal opioid activity.

Rosmarinic acid

Hydrocortisone butyrate

Hydrocortisone probutate